merck fda - Search News

News

Merck, RSV and FDA

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Reuters on MSN · 4d

US FDA approves Merck's RSV antibody for infants

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.

STAT · 4d

Merck’s RSV antibody treatment for infants is approved by FDA

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

18h

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck Receives FDA Approval for Treatment of Head, Neck Cancers

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

1don MSN

Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

Fierce Pharma4d

Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

STAT9d

Pharmalittle: We’re reading about Merck eyeing a biotech, a Moderna Covid vaccine trial, and more

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug ...

4don MSN

Merck's potential blockbuster cholesterol pill succeeds in late-stage studies

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results